AEArdalan Ebrahimi

Ardalan Ebrahimi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ardalan Ebrahimi has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • James Wykes

    Department of Head and Neck Surgery Liverpool Hospital Sydney New South Wales Australia

    6 shared publications
  • Jonathan R. Clark

    Sydney Head and Neck Cancer Institute Chris O'Brien Lifehouse Sydney New South Wales Australia

    6 shared publications
  • David Roshan

    Department of Head and Neck Surgery, Liverpool Hospital, Sydney, New South Wales, Australia

    5 shared publications
  • Ruta Gupta

    Sydney Head and Neck Cancer Institute Chris O'Brien Lifehouse Sydney New South Wales Australia

    4 shared publications
  • Allan Fowler

    Department of Radiation Oncology Liverpool Hospital Sydney New South Wales Australia

    3 shared publications
  • Ashish Sood

    Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia

    3 shared publications

Latest Publications

  • Open Access

    Evolution of Head and Neck Cutaneous Squamous Cell Carcinoma Nodal Staging—An Australian Perspective

    by Michael J. L. Hurrell, Tsu-Hui (Hubert) Low, Ardalan Ebrahimi, Michael Veness, Bruce Ashford, Sandro Porceddu, Jonathan R. Clark

    Cutaneous squamous cell carcinoma of the head and neck (HNcSCC) is one of the commonest malignancies. When patients present with regional metastatic disease, treatment escalation results in considerable morbidity and survival is markedly reduced. Owing to the high incidence, Australian institutions have been at the forefront of advocating for reliable, accurate, and clinically useful staging systems that recognise the distinct biological characteristics of HNcSCC. As a result, an extensive body of literature has been produced over the past two decades, which has defined critical prognostic factors, critiqued existing staging systems, and proposed alternative staging models. Notwithstanding, a suitable staging system has proved elusive. The goal of cancer staging is to group patients according to cancer characteristics for which survival differs between groups (distinctiveness), consistently decreases with increasing stage (monotonicity), and is similar within a group (homogeneity). Despite implementing major changes based on published data, the latest edition of the American Joint Committee on Cancer (AJCC) staging manual fails to satisfy these fundamental requirements. This review chronologically explores and summarises the Australian contribution to prognostication and nodal staging of HNcSCC and highlights the ongoing challenges.


  • The significance of regional metastasis location in head and neck cutaneous squamous cell carcinoma

    by Craig P. Mooney, Jonathan R. Clark, Kerwin Shannon, Carsten E. Palme, Ardalan Ebrahimi, Kan Gao, Sydney Ch'Ng, Michael Elliott, Ruta Gupta, Tsu‐Hui ( Hubert) Low

    Background Regional metastasis of head and neck cutaneous squamous cell carcinoma (HNcSCC) can be seen in either parotid and/or cervical lymph nodes. The aim of this study was to assess whether there was a difference in prognosis between parotid and cervical nodal metastases. Methods Patients with regional metastasis from HNcSCC were identified from an institutional database. Disease-specific (DSS) and overall survival (OS) were calculated using the Kaplan-Meier method and Cox proportional hazards models. Results Five hundred and thirty-five patients were identified with median follow-up of 26.4 months (3-255 months). Two hundred and thirty-five patients had parotid metastasis, 96 patients had neck metastasis, and 204 patients had both. On multivariable analysis, any regional metastasis to the neck when compared to parotid alone conferred worse DSS (HR 1.8, p = 0.007) and OS (HR 1.3, p = 0.024). Conclusion Regional metastasis of HNcSCC to the neck confers worse outcomes compared to metastasis to the parotid alone.


  • A critical analysis of the 8th edition TNM staging for head and neck cutaneous squamous cell carcinoma with lymph node metastases and comparison to N1S3 stage and ITEM risk score: A multicenter study

    by Ardalan Ebrahimi, Peter P. Luk, Hubert Low, Lachlan McDowell, Matthew J. R. Magarey, Paul N. Smith, Diana M. Perriman, Michael Veness, Ruta Gupta, Jonathan R. Clark

    Background and Objectives: We performed a critical analysis of the 8th edition American Joint Committee on Cancer (AJCC) staging for head and neck cutaneous squamous cell carcinoma (HNcSCC) with nodal metastases and compared the performance to the N1S3 and ITEM systems.Methods: Multicenter study of 990 patients with metastatic HNcSCC treated with curative intent. The end points of interest were disease‐specific (DSS) and overall survival (OS). Model fit was evaluated using Harrell's Concordance Index (C‐index), proportion of variation explained (PVE), Akaike information criterion, and Bayesian information criterion.Results: N1S3 and ITEM demonstrated good distribution into risk categories in contrast to the AJCC system, which classified the majority (90.6%) of patients as N2‐3 and Stage IV due to the high rate of extranodal extension. The N2c and N3a categories appeared redundant. There was considerable discordance between systems in risk allocation on an individual patient basis. N1S3 was the best performed (DSS: C‐index 0.62, PVE 10.9%; OS: C‐index 0.59, PVE 4.5%), albeit with relatively poor predictive value.Conclusions: The AJCC N category and tumor node metastasis stage have poor patient distribution and predictive performance in HNcSCC. The AJCC stage, N1S3, and ITEM score all provide limited prognostic information based on objective measures highlighting the need to develop a staging system specific to HNcSCC.


  • Number of nodal metastases and the American Joint Committee on cancer staging of head and neck cutaneous squamous cell carcinoma: A multicenter study

    by Ardalan Ebrahimi, Ruta Gupta, Peter Luk, Tsu-Hui (Hubert) Low, Lachlan McDowell, Matthew J.R. Magarey, Paul N. Smith, Diana M. Perriman, Klaus-Martin Schulte, Michael Veness, et al.


  • Nodal metastasis size predicts disease‐free survival in cutaneous head and neck squamous cell carcinoma involving the parotid but not cervical nodes

    by Ashish Sood, James Wykes, John McGuinness, Allan Fowler, Ardalan Ebrahimi

    Background: The 8th edition American Joint Committee on Cancer nodal (N) staging of cutaneous squamous cell carcinoma of the head and neck (cSCCHN) is largely based on lymph node metastasis size, despite conflicting data in the literature. This study aimed to investigate the prognostic significance of largest node size in cSCCHN.Methods: Retrospective analysis of 94 patients undergoing curative‐intent treatment for nodal cSCCHN with surgery ± radiotherapy at Liverpool Hospital, Sydney, Australia was conducted. Survival outcomes were assessed using multivariate Cox regression. The primary end point was disease‐free survival (DFS). Objective measures of model performance were used in exploratory analyses to identify optimal size thresholds for predicting survival.Results: Nodal metastasis size significantly predicted DFS on multivariate analysis (hazard ratio 1.24; 95% confidence interval 1.06–1.46; P = 0.008). This prognostic impact occurred predominantly in parotid metastases (hazard ratio 1.27; 95% confidence interval 1.07–1.51; P = 0.006); each 1 cm increase in size increased the risk of recurrence or death by 27%, irrespective of the number of involved nodes. In parotid metastases, size thresholds of ≤3, 3–4.5 and >4.5 cm optimized prognostic discrimination. Extranodal extension (ENE) was associated with decreased DFS in nodes ≤3 cm in size (P = 0.025), but not in those >3 cm (P = 0.744).Conclusion: Size is an important prognostic factor in cSCCHN with parotid metastases, with optimal thresholds of ≤3, >3–4.5 and >4.5 cm. The prognostic impact of ENE was seen only in nodal metastases ≤3 cm in size. These results may have important implications for node size thresholds and inclusion of ENE in the American Joint Committee on Cancer N staging categories.


  • Prognostic value of the 8th edition American Joint Commission Cancer nodal staging system for patients with head and neck cutaneous squamous cell carcinoma: A multi‐institutional study

    by Peter P. Luk, Ardalan Ebrahimi, Michael J. Veness, Lachlan McDowell, Matthew Magarey, Kan Gao, Carsten E. Palme, Jonathan R. Clark, Ruta Gupta

    Background: The 8th edition American Joint Committee on Cancer staging manual (AJCC8) introduced a separate staging system for head and neck cutaneous squamous cell carcinoma (HNcSCC) which parallels mucosal SCC and incorporates extranodal extension (ENE). This study aims to evaluate its prognostic utility.Methods: Univariate analysis of 1146 patients with metastatic HNcSCC from four Australian cancer centers was performed according to both AJCC 7th (AJCC7) and the 8th editions.Results: AJCC8 increased classification of 924 (80.6%) patients to either pN2a or pN3b and 341 patients (29.8%) from stage III to IV compared to AJCC7. The disease‐specific survival (DSS) was not significantly different between pN1, pN2 or pN3a categories per AJCC8. Estimates of model performance for the AJCC8 pN staging revealed modest predictive capacity (Harrell's C of 0.62 for DSS).Conclusions: The risk stratification according to pN classification of AJCC8 staging system performed poorly as a prognostic indicator.


  • The American Joint Committee on Cancer staging for metastatic head and neck cutaneous squamous cell carcinoma: A multi‐institutional study of within‐stage heterogeneity and impact on prognostic performance

    by Ardalan Ebrahimi, Peter P. Luk, Hubert Low, Lachlan McDowell, Matthew J. R. Magarey, Paul N. Smith, Diana M. Perriman, Bruce Shadbolt, Michael Veness, Ruta Gupta, et al.

    Background: The American Joint Committee on Cancer (AJCC) staging for head and neck cutaneous squamous cell carcinoma (HNcSCC) stratifies risk poorly. We hypothesized that this results from prognostic heterogeneity within N and TNM groups.Methods: Retrospective analysis of disease‐specific survival (DSS) in a multicenter study of 1146 patients with nodal metastases from HNcSCC.Results: The majority of patients were classified as pN2a or pN3b (83.1%) and TNM stage IV (90.6%). On multivariate analysis, there was statistically significant prognostic heterogeneity within these groups based on the number and size of nodal metastases, immunosuppression, and perineural invasion. When stage IV patients were categorized into low, moderate, and high‐risk groups based on adverse features, there was wide variation in prognosis with 5‐year DSS ranging from 90% to 60% (P < .001).Conclusions: The AJCC staging system stratifies risk poorly in HNcSCC due to significant prognostic heterogeneity within pN2a, pN3b, and stage IV groups.


  • Number of nodal metastases and prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck

    by Ashish Sood, James Wykes, David Roshan, Laura Y. Wang, John McGuinness, Dion Forstner, Allan Fowler, Mark Lee, Michael Kernohan, Quan Ngo, et al.

    Background: Existing prognostic systems for metastatic cutaneous squamous cell carcinoma of the head and neck (cSCCHN) do not discriminate between the number of involved nodes beyond single versus multiple. This study aimed to determine if the number of metastatic lymph nodes is an independent prognostic factor in metastatic cSCCHN and whether it provides additional prognostic information to the American Joint Committee on Cancer (AJCC) staging.Methods: We retrospectively analysed 101 patients undergoing curative intent treatment for metastatic cSCCHN to parotid and/or neck nodes by surgery +/− radiotherapy at Liverpool Hospital, Sydney, Australia. The impact of number of nodal metastases on disease‐free survival (DFS) and risk of distant metastases was assessed using multivariate Cox regression.Results: The mean number of nodal metastases was 2.5 (range 1–12). On multivariate analysis, increasing number of nodal metastases significantly predicted reduced DFS (hazard ratio 1.17; 95% confidence interval 1.05–1.30; P = 0.004), with a 17% increased risk of recurrence or death for each additional node. This remained significant in multivariate models adjusted for AJCC 8th edition nodal and TNM stages. Number of nodal metastases was also associated with risk of distant metastatic failure (hazard ratio 1.21; 95% confidence interval 1.05–1.39; P = 0.009).Conclusion: Increasing number of nodal metastases is associated with decreased DFS and increased risk of distant metastases in metastatic cSCCHN, with a cumulative risk increase with each additional node. It provides additional prognostic information to the AJCC staging, which may be improved by incorporating information on the number of nodal metastases beyond the current single versus multiple distinction.


  • Microscopic positive margins strongly predict reduced disease‐free survival in pT4a papillary thyroid cancer

    by Earl Abraham, David Roshan, Bryan Tran, Susannah Graham, Christopher Lehane, James Wykes, Peter Campbell, Ardalan Ebrahimi

    Background: Although microscopic positive margins appear to have no independent prognostic impact in papillary thyroid cancer (PTC), this may not be the case in pT4a tumors.Methods: Retrospective analysis of 610 patients with PTC, 39 with pT4a tumors, to determine if microscopic positive margins impact disease‐free survival (DFS) in pT4a PTC.Results: On univariate analysis, microscopic positive margins were not associated with reduced DFS in patients with no extrathyroidal extension (ETE) (hazard ratio [HR], 1.7; P = 0.32), microscopic ETE (HR, 1.6; P = 0.36), or macroscopic ETE limited to strap muscles (HR, 1.2; P = 0.87). In contrast, microscopic positive margins were associated with reduced DFS in T4a disease (HR, 4.1; P = 0.04). Disease recurrence was nodal, distant, or biochemical, and did not occur directly at the site of positive margins.Conclusion: Although microscopic positive margins do not influence DFS in the majority of patients with PTC, they are associated with a fourfold increased risk of recurrence in pT4a disease.


  • Depth of invasion alone as an indication for postoperative radiotherapy in small oral squamous cell carcinomas: An International Collaborative Study

    by Ardalan Ebrahimi, Ziv Gil, Moran Amit, Tzu‐Chen Yen, Chun‐Ta Liao, Pankaj Chaturvedi, Jai Prakash Agarwal, Luiz P. Kowalski, Hugo F. Köhler, Matthias Kreppel, et al.

    Background: We aimed to investigate whether depth of invasion (DOI) should be an independent indication for postoperative radiotherapy (PORT) in small oral squamous cell carcinomas (SCC).Methods: Retrospective analysis of DOI (P = .169), yielding an absolute risk difference of only 4%.Conclusion: The deterioration in prognosis with increasing DOI largely reflects an association with other adverse features. In the absence of these, depth alone should not be an indication for PORT outside a clinical trial.